Blocking VEGF by Bevacizumab Attenuates VEGF-Induced Vasospasm After Experimental Subarachnoid Hemorrhage in Rabbits
- 1 July 2020
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 139, e136-e143
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Attenuation of cerebral vasospasm and secondary injury by testosterone following experimental subarachnoid hemorrhage in rabbitActa Neurochirurgica, 2014
- Bevacizumab Attenuates VEGF-Induced Angiogenesis and Vascular Malformations in the Adult Mouse BrainStroke, 2012
- Reply: Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasiaLiver Transplantation, 2008
- Anti-vascular endothelial growth factor therapy for ocular neovascular diseaseCurrent Opinion in Ophthalmology, 2007
- Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumabAnnals of Hematology, 2006
- Role of Vascular Mitogens in Subarachnoid Hemorrhage-Associated Cerebral VasculopathyNeurocritical Care, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Amelioration of Vasospasm After Subarachnoid Hemorrhage in Transgenic Mice Overexpressing CuZn–Superoxide DismutaseStroke, 1999
- Inhibition of Experimental Vasospasm in Rats With the Periadventitial Administration of Ibuprofen Using Controlled-Release PolymersStroke, 1999
- Platelet derived growth factor and subarachnoid haemorrage: A study on cisternal cerebrospinal fluidActa Neurochirurgica, 1997